Abstract
Antiviral chemotherapy often relies on nucleoside analogues, which, once phophorylated by intracellular kinases, target viral polymerases impeding DNA synthesis. In contrast, nucleoside analogues are much less explored as antibacterial drugs. Thymidine monophosphate kinase from Mycobacterium tuberculosis (TMPKmt), which is essential to DNA replication, was selected as a promising target for the design of new inhibitors. This review describes stepwise modifications of the TMPKmt substrate, guided by the feedback of enzyme assays and crystallographic analysis to afford potent enzyme inhibitors some of which also exhibited antitubercular activity. More importantly, several of the reported thymidine analogues provided a deeper understanding of the structure and catalytic mechanism of this intriguing enzyme.
Keywords: Tuberculosis, kinase, nucleotide metabolism, inhibitors, structure-activity relationship, molecular modeling, Antiviral chemotherapy, enzyme assays, antibacterial drugs, intriguing enzyme, demographic factors, potent enzyme inhibitors, cancer chemotherapy, antimycobacterial drugs
Current Topics in Medicinal Chemistry
Title:Drug Design and Identification of Potent Leads Against Mycobacterium tuberculosis Thymidine Monophosphate Kinase
Volume: 12 Issue: 7
Author(s): S. Van Calenbergh, S. Pochet and H. Munier-Lehmann
Affiliation:
Keywords: Tuberculosis, kinase, nucleotide metabolism, inhibitors, structure-activity relationship, molecular modeling, Antiviral chemotherapy, enzyme assays, antibacterial drugs, intriguing enzyme, demographic factors, potent enzyme inhibitors, cancer chemotherapy, antimycobacterial drugs
Abstract: Antiviral chemotherapy often relies on nucleoside analogues, which, once phophorylated by intracellular kinases, target viral polymerases impeding DNA synthesis. In contrast, nucleoside analogues are much less explored as antibacterial drugs. Thymidine monophosphate kinase from Mycobacterium tuberculosis (TMPKmt), which is essential to DNA replication, was selected as a promising target for the design of new inhibitors. This review describes stepwise modifications of the TMPKmt substrate, guided by the feedback of enzyme assays and crystallographic analysis to afford potent enzyme inhibitors some of which also exhibited antitubercular activity. More importantly, several of the reported thymidine analogues provided a deeper understanding of the structure and catalytic mechanism of this intriguing enzyme.
Export Options
About this article
Cite this article as:
Van Calenbergh S., Pochet S. and Munier-Lehmann H., Drug Design and Identification of Potent Leads Against Mycobacterium tuberculosis Thymidine Monophosphate Kinase, Current Topics in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/156802612799984580
DOI https://dx.doi.org/10.2174/156802612799984580 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Stopping of the Downtrend of Tuberculosis in Iran, a Systematic Review of Associated Risk Factors
Infectious Disorders - Drug Targets Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Nanoemulsion-Based Transdermal Drug Delivery System for the Treatment of Tuberculosis
Recent Patents on Anti-Infective Drug Discovery Personalized and Predictive Medicine in Turkey: A Symposium Report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009
Current Pharmacogenomics and Personalized Medicine The Recent Electrochemical Biosensor Technologies for Monitoring of Nucleic Acid Hybridization
Current Analytical Chemistry Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design KEMREP: A New Qualitative Method for the Assessment of an Analyst’s Ability to Generate a Metabolomics Data Matrix by Gas Chromatography– Mass Spectrometry
Current Metabolomics Pulmonary Surfactant Proteins A and D: Innate Immune Functions and Biomarkers for Lung Diseases
Current Pharmaceutical Design Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report
Current Drug Safety Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs
Current Medicinal Chemistry Regulation of Inflammation and Myocardial Fibrosis in Experimental Autoimmune Myocarditis
Inflammation & Allergy - Drug Targets (Discontinued) Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Tuberculosis: An Inorganic Medicinal Chemistry Perspective
Current Medicinal Chemistry Meet Our Editorial Board Member
Drug Delivery Letters Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Synthesis and Antitubercular Evaluation on Novel 1-Ethyl-5-(hetero)aryl- 1,6-dihydropyrazine-2,3-dicarbonitriles and 3-Cyano-1-ethyl-5-(hetero) aryl-2(1H)-pyrazinones
Anti-Infective Agents Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents
Letters in Drug Design & Discovery